Cryocell International Stock Beneish M Score

CCEL Stock  USD 7.75  0.02  0.26%   
This module uses fundamental data of CryoCell International to approximate the value of its Beneish M Score. CryoCell International M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out CryoCell International Piotroski F Score and CryoCell International Altman Z Score analysis.
For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.
  
At this time, CryoCell International's Short and Long Term Debt is quite stable compared to the past year. Interest Debt Per Share is expected to rise to 1.25 this year, although the value of Net Debt will most likely fall to about 9 M. At this time, CryoCell International's ROIC is quite stable compared to the past year. Payout Ratio is expected to rise to 2.62 this year, although the value of PTB Ratio is projected to rise to (4.42).
At this time, it appears that CryoCell International is an unlikely manipulator. The earnings manipulation may begin if CryoCell International's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by CryoCell International executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of CryoCell International's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.58
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

2.06

Focus
Asset Quality

1.0

Focus
Expense Coverage

1.12

Focus
Gross Margin Strengs

0.85

Focus
Accruals Factor

1.12

Focus
Depreciation Resistance

1.0

Focus
Net Sales Growth

0.51

Focus
Financial Leverage Condition

0.97

Focus

CryoCell International Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if CryoCell International's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables7.9 M7.6 M
Sufficiently Up
Slightly volatile
Total Revenue18.4 M36 M
Way Down
Slightly volatile
Total Assets73.9 M70.4 M
Sufficiently Up
Slightly volatile
Total Current Assets10.5 M10.9 M
Sufficiently Down
Slightly volatile
Non Current Assets Total62.5 M59.5 M
Sufficiently Up
Slightly volatile
Property Plant Equipment17.2 M16.3 M
Sufficiently Up
Slightly volatile
Depreciation And Amortization2.1 MM
Sufficiently Up
Slightly volatile
Selling General Administrative11.2 M19.7 M
Way Down
Slightly volatile
Total Current Liabilities25.2 M24 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total62.1 M59.1 M
Sufficiently Up
Slightly volatile
Short Term Debt1.6 M1.9 M
Fairly Down
Slightly volatile
Long Term Debt5.2 M9.7 M
Way Down
Slightly volatile
Total Cash From Operating Activities10.8 M10.3 M
Sufficiently Up
Slightly volatile
Short Term Investments641.7 K516.8 K
Fairly Up
Slightly volatile
Gross Profit Margin0.560.66
Fairly Down
Slightly volatile

CryoCell International Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between CryoCell International's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards CryoCell International in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find CryoCell International's degree of accounting gimmicks and manipulations.

About CryoCell International Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Total Assets

73.92 Million

At this time, CryoCell International's Total Assets are quite stable compared to the past year.

CryoCell International Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as CryoCell International. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables6.3M5.3M6.0M6.6M7.6M7.9M
Total Revenue31.1M28.9M30.3M31.3M36.0M18.4M
Total Assets46.2M60.7M64.9M61.2M70.4M73.9M
Total Current Assets18.6M15.8M9.6M9.5M10.9M10.5M
Net Debt(4.1M)(5.4M)9.9M10.5M9.4M9.0M
Short Term Debt3.4M2.2M2.7M1.6M1.9M1.6M
Long Term Debt5.9M2.8M8.6M8.4M9.7M5.2M
Operating Income7.7M4.0M4.0M(12.3M)(14.1M)(13.4M)
Investments457.4K(7.0M)(15.3M)(8.1M)(7.3M)(7.0M)

CryoCell International ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CryoCell International's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CryoCell International's managers, analysts, and investors.
Environmental
Governance
Social

About CryoCell International Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CryoCell International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CryoCell International using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CryoCell International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether CryoCell International is a strong investment it is important to analyze CryoCell International's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CryoCell International's future performance. For an informed investment choice regarding CryoCell Stock, refer to the following important reports:
Check out CryoCell International Piotroski F Score and CryoCell International Altman Z Score analysis.
For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.625
Earnings Share
(1.07)
Revenue Per Share
3.89
Quarterly Revenue Growth
0.025
Return On Assets
(0)
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.